Craft

Tanvex BioPharma

Stock Price

NT$64.3

2024-02-05

Market Capitalization

NT$8.6 B

2024-02-05

Revenue

NT$22.4 M

FY, 2022

Tanvex BioPharma Summary

Company Summary

Overview
Tanvex BioPharma (formerly known as Ruenvex Biotech) is a company that manufactures and develops biosimilar and biologic products and drugs. It offers biosimilars targeting neutropenia, breast cancer, metastatic colorectal cancer, and psoriasis.
Type
Public
Status
Active
Founded
2013
HQ
Taipei, TW | view all locations
Website
http://www.tanvex.com/
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Allen Chao

    Allen Chao, Founder, Honorary Chairman of the Board of Directors

    • Yun Yen

      Yun Yen, Chairman & CEO

      • Ula Xue, Director

        • Chen Chi-Chuan, Director

          Operating MetricsView all

          Facility Space (US), sq. ft.

          135K
          23.9%

          FY, 2020

          LocationsView all

          5 locations detected

          • Taipei, Taipei City HQ

            Taiwan

            13F.-1, No.376, Sec. 4, Ren’ai Rd., Da’an Dist.

          • Irvine, CA

            United States

            2030 Main Street, Suite 600

          • San Diego, CA

            United States

            10394 Pacific Center Ct

          • San Diego, CA

            United States

            10421 Pacific Center Court, Suite 100

          • New Taipei, New Taipei City

            Taiwan

            33F., No.99, Sec. 1, Xintai 5th Rd., Xizhi Dist.

          Tanvex BioPharma Financials

          Summary Financials

          Revenue (Q3, 2023)
          NT$5.1M
          Gross profit (Q3, 2023)
          NT$4.5M
          Net income (Q3, 2023)
          (NT$505.3M)
          Cash (Q3, 2023)
          NT$873.8M
          EBIT (Q3, 2023)
          (NT$507.1M)
          Enterprise value
          $9.6B

          News

          Footer menu